Potential benefit of osimertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer
Cited by 26
Related Papers
Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non–Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01)
|Journal of Clinical Oncology|2022|177
Dual efficacy of tocilizumab in managing PD-1 inhibitors-induced myocardial inflammatory injury and suppressing tumor growth with PD-1 inhibitors: a preclinical study
|Cancer Immunology Immunotherapy|2025|10
Uncommon/rare oncogenic drivers in non‐small cell lung cancer: Consensus and contention
|Medicine Advances|2023|8
Clinical definition of secondary resistance to immunotherapy in non‐small cell lung cancer
|Thoracic Cancer|2023|5